KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBT: 2013-2025

Historic EBT for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.2 million.

  • Xenon Pharmaceuticals' EBT fell 42.96% to -$90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$314.7 million, marking a year-over-year decrease of 47.17%. This contributed to the annual value of -$243.4 million for FY2024, which is 33.24% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' EBT stood at -$90.2 million, which was down 5.73% from -$85.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' EBT's 5-year high stood at -$15.7 million during Q3 2021, with a 5-year trough of -$90.2 million in Q3 2025.
  • Its 3-year average for EBT is -$60.6 million, with a median of -$58.3 million in 2024.
  • Data for Xenon Pharmaceuticals' EBT shows a maximum YoY slumped of 10,332.71% (in 2021) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' EBT (Quarterly) stood at -$25.1 million in 2021, then plummeted by 44.56% to -$36.3 million in 2022, then decreased by 23.97% to -$44.9 million in 2023, then slumped by 65.80% to -$74.5 million in 2024, then slumped by 42.96% to -$90.2 million in 2025.
  • Its EBT was -$90.2 million in Q3 2025, compared to -$85.3 million in Q2 2025 and -$64.6 million in Q1 2025.